Chubu Electric's Nuclear Restart Dies With Its Rigged Seismic Data

TOKYO BASE's first-half revenue jumped 21.1% largely on tax-free tourist spending, which supplied 72% of the increase in domestic store sales, while like-for-like sales slipped at UNITED TOKYO, PUBLIC TOKYO and CITY, the company's own original formats.

HUMAN MADE agreed to pay ¥538.8mn in cash for full control of UNDERCOVER's operating company, but the deal won't close until February 2027 and the filing does not yet say how much goodwill it will generate.

Six-month sales at the Sabae eyewear group rose 14.8% to \u00a510.26bn as price increases and inbound tourist demand drove a 20% jump at its main brand, even as the group's second brand grew just 4.5% on slower overseas wholesale.

SanBio's cell therapy for chronic traumatic brain injury, known by its development code SB623, cleared its final approval hurdle and reached the market in 2026 with a ¥72mn price tag, yet the company's latest results show no product revenue, a shrinking cash pile, and a 20.29% cut to capital to offset accumulated losses.

Mori Hills REIT kept its distribution at ¥3,100 per unit even as net income fell 5.2%, covering the shortfall with a reserve drawdown and a ¥1.257bn gain from selling part of its Laforet Harajuku land stake, a pattern management plans to repeat for two more periods.

SAMCO, the Kyoto semiconductor-equipment maker, closed the year to July 2026 with sales up 15.6% to ¥10.8bn and a year-end order backlog that more than doubled to ¥11.46bn, while compound-semiconductor sales grew 45.9% and sales linked to plain silicon wafers dropped by more than half.

Placement and job-fair revenue jumped at recruiting firm Gakujo while its core job board barely grew, because Japanese graduates now hold 1.46 informal offers each on average, up from 1.26 a year ago, and are declining the ones they don't want later than before.

Enigmo's free-float market value, at ¥9.04bn, remains below the ¥10bn Tokyo Stock Exchange Prime threshold, and the BUYMA operator has until the end of January to close the gap even as consolidated first-half losses widened and the core marketplace's transaction volume kept sliding.

AEON Fantasy's board has ordered the dissolution of its Beijing children's-amusement subsidiary, which had run up negative net worth of about 810 million yuan after years of pandemic-hit, competition-squeezed losses, and the company is first converting ¥19.4bn of loan claims into equity and injecting ¥4.3bn more capital before the wind-down completes around the year ending February 2028.

A Tokyo court dismissed a shareholder's injunction bid against SAAF Holdings' takeover-defense warrants, ruling the dilutive treatment was justified because a 19-member investor group had concealed a joint stake to evade large-shareholding disclosure rules, and the company said it would carry out the allocation as planned on that day's record date.

AVALDATA Corporation will pay ¥690 in cash per share, a 112% premium to the prior close, to absorb a smaller Tokyo-listed maker of image-compression technology that was already set to lose its listing over a free-float shortfall before shareholders vote on the buyout in November.

MUFG Bank is lending Nippon Seiki an unsecured ¥50bn for one year to fund its Toyo Densou acquisition, and the loan bars two straight years of consolidated pretax losses starting with the year ending March 2027, with refinancing into longer-term debt still to be arranged before the September 2027 deadline.

Ariake Capital's stake in Tokyo Kiraboshi Financial Group climbed to 9.00% on client-funded market buying since July, and its filing reserves the right to press capital-policy or restructuring proposals, though none has been made so far.

Ureru Net Advertising Group's shareholders' equity turned negative at the end of its year to July 2026 after a net loss that widened to ¥1.11bn, breaching the Tokyo Stock Exchange's minimum net-asset standard for Growth Market companies; the firm says a share exchange and share deliveries completed on August 10 already pushed net assets back into positive territory, though a formal compliance plan for the listing rule has yet to be published.

Smaregi's operating profit rose 73.3% in the quarter through July as recurring subscription revenue and newly in-housed cashless-payment processing pushed its margin to 28.5%, even though the company left its full-year sales and profit targets unchanged.

Sony Group spent ¥43.48bn repurchasing shares in August, bringing its ¥500bn buyback authorization to 47.47% completion by value and 29.38% by share count, with the program running through May 2027 and more than half the authorized spending still available.

Healthcare & Medical Investment Corporation tapped an ¥8.8bn share sale and lined up ¥11.1bn in bank loans to acquire 14 senior-care properties and a Tokyo hospital site, a deal that pushes its portfolio toward the largest healthcare-property base among Japan's listed REITs and reshapes near-term payout guidance.

Financial Services Agency data for April to June show 1,616 of the 1,961 reported fraudulent investment pitches already involved some form of harm to the complainant, even as crypto-asset complaints eased and everyday investment queries climbed to 5,603.

Japan's financial regulator says a company listed at a British Virgin Islands address has been lending money over the internet through a service called CryptoPawn without registering as a moneylender, and it cannot identify who runs it.

Market participants have until December 1 to comment, in English, on two consultation papers from BIS's payments committee and IOSCO covering cyber resilience and third-party vendor dependency at financial market infrastructure, after Japan's FSA posted a notice pointing to the original documents.

The FDA has accepted Takeda's application for zasocitinib, a once-daily pill for moderate-to-severe plaque psoriasis, for priority review, with a decision due in the first quarter of 2027; across two phase 3 trials roughly 70% of patients reached clear or almost-clear skin by 16 weeks, well ahead of both placebo and the comparator drug apremilast, though Takeda says the filing itself does not change its earnings outlook for the year to March 2027.